Procalcitonin News and Research

RSS

EKF highlighting its expanding range of liquid stable clinical chemistry reagents at Hospitalar 2015

EKF Diagnostics will be highlighting its expanding Stanbio central laboratory clinical chemistry range at Hospitalar, 19–22 May, Sao Paulo, Brazil.

From EKF Diagnostics 14 May 2015

EKF introduces specific biomarker test for early sepsis identification

EKF Diagnostics, the global diagnostics company, announces that it has introduced the Stanbio Chemistry Procalcitonin (PCT) LiquiColor® Assay.

From EKF Diagnostics 7 May 2015

EKF highlighting heat and humidity compatible POC hemoglobin analyzer at Arab Health 2015

EKF Diagnostics, the global diagnostics company, announces that it will be highlighting the robustness of its new DiaSpect Tm POC hemoglobin analyzer.

From EKF Diagnostics 15 Jan 2015

Randox's Acusera Immunoassay Speciality 1 quality control receives FDA clearance

In Q3 of 2013, Randox announced that the Food and Drug Administration has approved the company's Acusera Immunoassay Speciality 1 quality control for use in US laboratories.

From Randox Laboratories Ltd. 22 Jul 2014

First publication describing use of CytoSorb during cardiac surgery

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber in multiple countries worldwide, announced the PDF availability of the first publication describing the use of CytoSorb® intra-operatively during cardiac surgery at the Ludwig Maximilian University of Munich Hospital - Grosshadern Campus, in Germany.

17 Jul 2014

Specific inflammatory pattern found in patients with pneumonia and COPD

Patients with community-acquired pneumonia on a background of chronic obstructive pulmonary disease have a different early inflammatory pattern than patients with CAP only, a prospective study shows.

30 Apr 2013

Specific inflammatory pattern found in patients with pneumonia and COPD

Patients with community-acquired pneumonia on a background of chronic obstructive pulmonary disease have a different early inflammatory pattern than patients with CAP only, a prospective study shows.

29 Apr 2013

Procalcitonin levels help distinguish between pneumonia types

Serum procalcitonin is a useful marker for distinguishing between acute exacerbation of interstitial pneumonia and bacterial pneumonia, say researchers.

26 Nov 2012

Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed a long-term license agreement with Fujirebio Inc. to make its biomarker assay Procalcitonin (PCT) available on the Lumipulse family of laboratory instruments, using the chemiluminescent enzyme immunoassay (CLEIA) technology.

From Thermo Fisher Scientific Inc. 21 Nov 2012

Calcium-related hormone could help identify pneumonia

Serum procalcitonin measurements could improve the accuracy of pneumonia diagnoses when chest radiographs give indeterminate results, indicate US study findings.

12 Nov 2012

Procalcitonin good marker of bacteremia in children with central lines

High procalcitonin levels are a good indicator of bacteremia in children with a central venous catheter who present to the emergency department with fever, suggest study findings.

30 Oct 2012

Levels of body chemical PCT influence duration of antibiotic use

Measuring the levels of a natural body chemical may allow doctors to reduce the duration of antibiotic use and improve the health outcomes of critically ill patients.

5 Aug 2011

Majority of nurses are unaware of simple diagnostic test for sepsis

bioMerieux, a world leader in the field of in vitro diagnostics, announced the results of a survey demonstrating that most critical care nurses are unaware of a simple diagnostic test that may dramatically improve outcomes for sepsis patients.

22 Dec 2010

European Patent Office to grant patent for R&D Antibodies’ immunoassays and apparatuses

Research & Diagnostic Antibodies LLC (R&D Antibodies) announced today that it has received a notification stating that the European Patent Office intends to grant a patent for its monoclonal antibody-based immunoassays and apparatuses for measuring inducible nitric oxide synthase (iNOS) as a plasma biomarker for the early detection of the sepsis pathology.

28 Oct 2009

Thermo Fisher Scientific to acquire B.R.A.H.M.S. for $470 million

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has signed a definitive agreement to acquire B.R.A.H.M.S. AG for €330 million (approximately $470 million USD). B.R.A.H.M.S. is a leading provider of specialty in-vitro diagnostic tests based on its patented biomarkers for sepsis, cardiovascular and pulmonary diseases, as well as intensive care treatments and prenatal screening.

From Thermo Fisher Scientific Inc. 3 Sep 2009

Simple blood test could help detect serious bacterial infections in babies

A simple blood test may help detect serious bacterial infections (SBIs) like urinary tract infections and blood stream infections in young infants who come to the emergency department (ED) with fevers that have no clear cause.

6 Oct 2008

New diagnostic tools and biomarkers

Patients presenting shortness of breath on arrival at the emergency department (ED) can gain from improved diagnosis allowing physicians to distinguish congestive heart failure patients from those presenting pneumonia.

1 Sep 2008

Procalcitonin: A valuable predicator for lethal respiratory failure

High levels or persistent elevation of PCT in patients with severe pneumonia usually results in death. According to a study in Respirology published by Wiley-Blackwell, Procalcitonin (PCT) levels in patients are indicative of survival rates, proving to be a valuable prognostic factor of Acute Respiratory Distress Syndrome (ARDS).

22 May 2008

Customized treatments for sepsis lower treatment time and reduce length of ICU stays

Using a blood test and a decision algorithm, rather than standard hospital protocols, to determine the appropriate length of antibiotic therapy in patients with severe sepsis or septic shock can reduce duration of treatments, shorten ICU stays, and lower hospital costs - all without adverse effects on patients, according to new research.

1 Mar 2008

Procalcitonin helps predict prognosis among those with peritonitis

Monitoring blood levels of a compound known as procalcitonin in patients with peritonitis (a serious intra-abdominal infection) could help identify patients at increased risk of organ failure and death, according to a report in the February issue of Archives of Surgery.

20 Feb 2007